13F-HR filed by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC filed this 13F-HR for the quarter ended 2024-06-30, filed 2024-08-14, with 41 holding rows worth $7,508,400,483.
- Accession
- 0001104659-24-089335
- Filer
- CIK 1633313
- Filed
- 2024-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2024
A holdings report, 41 entries on the cover page, a total value of $7,508,400,483 stated on the cover page (in dollars after the unit check, H1), rows summing to $7,508,400,483 with VALUE read as dollars as filed, 13F file number 028-16573. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 2,858,888 | $910,698,772 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 2,055,555 | $575,884,289 | dollars as filed | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 4,196,661 | $572,340,627 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 1,238,467 | $532,590,349 | dollars as filed | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 3,000,000 | $474,000,000 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 2,433,000 | $446,796,120 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 11,111,111 | $426,222,218 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 4,557,416 | $375,212,059 | dollars as filed | |
| CEREVEL THERAPEUTICS HLDNG I | 15678U128 | COM | 7,539,547 | $308,292,077 | dollars as filed | |
| SPDR SER TR | 78464A870 | S&P BIOTECH | 3,035,000 | $281,374,850 | dollars as filed | |
| AMICUS THERAPEUTICS INC | 03152W109 | COM | 27,400,000 | $271,808,000 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 6,505,000 | $265,729,250 | dollars as filed | |
| ARROWHEAD PHARMACEUTICALS IN | 04280A100 | COM | 8,888,888 | $231,022,199 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 5,666,666 | $220,943,307 | dollars as filed | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 3,000,000 | $205,470,000 | dollars as filed | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 4,309,590 | $155,920,966 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 2,770,000 | $121,796,900 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 3,888,888 | $116,083,307 | dollars as filed | |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 400,000 | $97,200,000 | dollars as filed | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 11,700,000 | $93,834,000 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 2,091,666 | $85,339,973 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 1,355,000 | $80,175,350 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 3,888,437 | $79,829,612 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 12,570,000 | $77,682,600 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 3,541,505 | $72,919,588 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 8,060,000 | $55,130,400 | dollars as filed | |
| MANNKIND CORP COM NEW | 56400P706 | Stock | 8,759,524 | $45,724,715 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 575,000 | $43,418,250 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 1,839,138 | $43,238,134 | dollars as filed | |
| AUTOLUS THERAPEUTICS PLC SPON | 05280R100 | COM | 12,345,678 | $42,962,959 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 18,650,000 | $41,776,000 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 830,000 | $34,113,000 | dollars as filed | |
| VERRICA PHARMACEUTICALS INC | 92511W108 | COM | 3,999,999 | $29,159,993 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 2,222,222 | $28,577,775 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 700,000 | $22,099,000 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 4,535,000 | $16,960,900 | dollars as filed | |
| BICYCLE THERAPEUTICS PLC-ADR | 088786108 | SPONSORED ADS | 700,000 | $14,168,000 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 2,849,402 | $4,160,127 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 115,751 | $4,084,853 | dollars as filed | |
| ADVERUM BIOTECHNOLOGIES INC | 00773U207 | COM NEW | 416,666 | $2,858,329 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 22,029 | $801,635 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-24-089335 | this filing | 2024-08-14 | acceptance time not in the bulk data set |